In an article in The College of American Pathologists’ (CAP) Precision Medicine, pathologists report that dd-cfDNA is a leading indicator of de novo donor-specific antibody (DSA) development and a significantly better discriminator of transplant rejection or allograft injury than serum creatinine.
For the full article click here: Donor‑Derived Cell‑Free DNA May Aid Monitoring of Kidney Transplant Recipients